Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 870 results
Filters: Author is Bosch, Ronald J  [Clear All Filters]
Found 870 results.


Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
Ribaudo HJ, Benson CA, Zheng Y, et al. "No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT." Clin. Infect. Dis.. 2011;52(7):929-40.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
Smurzynski M, Wu K, Letendre S, et al. "Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort." AIDS. 2011;25(3):357-65.
Rosenberg ES, Graham BS, Chan ES, et al. "Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection." PLoS ONE. 2010;5(5):e10555.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.
Mollan K, Daar ES, Sax PE, et al. "HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status." J. Infect. Dis.. 2012;206(12):1920-30.
Deeks SG, Gange SJ, Kitahata MM, et al. "Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America." Clin. Infect. Dis.. 2009;49(10):1582-90.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Smurzynski M, Collier AC, Koletar SL, et al. "AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics." HIV Clin Trials. 2008;9(4):269-82.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Chen H, Clifford DB, Deng L, et al. "Peripheral neuropathy in ART-experienced patients: prevalence and risk factors." J. Neurovirol.. 2013;19(6):557-64.
Weinberg A, Tierney C, Kendall MA, et al. "Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy." J. Infect. Dis.. 2006;193(4):488-93.
Besson GJ, Lalama CM, Bosch RJ, et al. "HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy." Clin. Infect. Dis.. 2014;59(9):1312-21.
Smurzynski M, Wu K, Schouten JT, et al. "Factors associated with remaining on initial randomized efavirenz-containing regimens." AIDS. 2013;27(12):1887-97.